Actinium Pharma (ATNM)
1.38
-0.02 (1.43%)
Upcoming Events
Latest Headlines
Actinium shares early ATNM-400 prostate cancer trial data at EANM
October 20, 2026 8:03 AM - StreetInsider
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
October 20, 2026 8:01 AM - PR NewsWire
Actinium shares preclinical data on ATNM-400 across three cancer types
October 20, 2026 7:31 AM - StreetInsider
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
October 20, 2026 7:30 AM - PR NewsWire
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
October 19, 2026 7:30 AM - PR NewsWire
Form 4 Actinium Pharmaceuticals For: Oct 14 Filed by: David Matthew T
October 16, 2026 5:11 PM - SEC Filing
Form 3 Actinium Pharmaceuticals For: Oct 14 Filed by: David Matthew T
October 16, 2026 5:11 PM - SEC Filing
Actinium Pharmaceuticals Announces Inducement Grants to New Employees
October 16, 2026 5:00 PM - PR NewsWire
Actinium to present ATNM-400 cancer data at EANM 2026
October 16, 2026 8:31 AM - StreetInsider
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
October 16, 2026 8:30 AM - PR NewsWire
Form ARS Actinium Pharmaceuticals For: Dec 31
October 16, 2026 7:51 AM - SEC Filing
Form DEF 14A Actinium Pharmaceuticals For: Nov 25
October 16, 2026 7:43 AM - SEC Filing
Actinium Pharmaceuticals names Sean Maenpaa as SVP of business development
October 16, 2026 7:30 AM - StreetInsider
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development
October 16, 2026 7:30 AM - PR NewsWire
Form 8-K Actinium Pharmaceuticals For: Oct 14
October 15, 2026 5:05 PM - SEC Filing
Actinium to present Phase 1 data on ATNM-400 at EANM 2026
October 15, 2026 8:30 AM - StreetInsider
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
October 15, 2026 8:30 AM - PR NewsWire
Actinium Pharmaceuticals names Matt David as CFO
October 15, 2026 7:31 AM - StreetInsider
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
October 15, 2026 7:30 AM - PR NewsWire
Form S-8 Actinium Pharmaceuticals
October 9, 2026 5:01 PM - SEC Filing
Form 3 Actinium Pharmaceuticals For: Sep 03 Filed by: Heeger Steffen Wilhem
September 10, 2026 5:00 PM - SEC Filing
Form 3 Actinium Pharmaceuticals For: Sep 03 Filed by: Kamal Adeela
September 10, 2026 5:00 PM - SEC Filing
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 4, 2026 5:05 PM - PR NewsWire
Form 4 Actinium Pharmaceuticals For: Sep 02 Filed by: Nicholson, C. David
September 4, 2026 5:01 PM - SEC Filing
Form 4 Actinium Pharmaceuticals For: Sep 02 Filed by: SETH SANDESH
September 4, 2026 5:01 PM - SEC Filing
Form 4 Actinium Pharmaceuticals For: Sep 02 Filed by: Almenoff June Sherie
September 4, 2026 5:01 PM - SEC Filing
Form 4 Actinium Pharmaceuticals For: Sep 02 Filed by: Shetty Ajit
September 4, 2026 5:01 PM - SEC Filing
Form 4 Actinium Pharmaceuticals For: Sep 02 Filed by: Steinhart Richard I
September 4, 2026 5:01 PM - SEC Filing
Form 4 Actinium Pharmaceuticals For: Sep 02 Filed by: Chell Jeffrey W.
September 4, 2026 5:00 PM - SEC Filing
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
August 14, 2026 5:02 PM - PR NewsWire
Form 8-K Actinium Pharmaceuticals For: Aug 12
August 14, 2026 5:01 PM - SEC Filing
Form 10-Q Actinium Pharmaceuticals For: Jun 30
August 7, 2026 5:01 PM - SEC Filing
Full Article List
